Novo Nordisk’s hopes of heralding a new era of obesity treatment with its next-generation CagriSema drug may be in doubt ...
The Allegations: Rosen Law Firm is Investigating the Allegations that Novo Nordisk A/S (NYSE: NVO) Misled Investors Regarding its Business Operations.
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
The phase 3 REDEFINE 2 trial has been evaluating once-weekly subcutaneous CagriSema, a fixed dose combination of cagrilintide ...
Novo Nordisk announced disappointing data from a phase III study on a novel obesity candidate, CagriSema. Roche announced a ...
Topline data were announced from a phase 3 trial evaluating CagriSema (cagrilintide/semaglutide) in overweight or obese patients with type 2 diabetes.
Denmark: CagriSema has demonstrated superior weight loss in adults with obesity or overweight and type 2 diabetes in the ...
NVO reports disappointing data from a phase III study on a novel obesity candidate, CagriSema. RHHBY buys rights to obesity candidate from Zealand Pharma.
Zacks Investment Research on MSN12d
NVO Stock Down 9% as CagriSema Misses Target in Second Obesity StudyNovo Nordisk NVO has achieved the primary endpoint in the second late-stage study evaluating its next-gen subcutaneous ...
Novo Nordisk's REDEFINE 2 trial shows CagriSema led to significant weight loss in patients with obesity and type 2 diabetes. Regulatory filing is planned for 2026.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback